Trial reportBone marrow transplantation2015
The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02419118 ("Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab "), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab "
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.Current oncology (Toronto, Ont.) · 2024Trial
- Myeloid-Derived Suppressor Cells (MDSCs) Suppress T-Cell Proliferation Less Than Mature Neutrophils in Blood and Bone Marrow From Multiple Myeloma Patients.Journal of immunology research · 2026Article
- What happens to regulatory T cells in multiple myeloma.Cell death discovery · 2023Review
- The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.Frontiers in oncology · 2023Article
- Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.Cancers · 2021Article
- The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).Journal of clinical medicine · 2021Review
- Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.Frontiers in immunology · 2021Review
- Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.Clinical lymphoma, myeloma & leukemia · 2020Article
- Review
- Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis.Journal of cellular physiology · 2019Article
- Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.International journal of molecular sciences · 2019Review
- Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Drugs · 2018Review
- Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.Blood cancer journal · 2017Review
- Is immunotherapy here to stay in multiple myeloma?Haematologica · 2017Review
- Myeloid-derived suppressor cells: The green light for myeloma immune escape.Blood reviews · 2016Review
- Myeloid-derived suppressor cells in B cell malignancies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic graft-versus-tumor (GVT) effect is moderate and not sustained, implying that immune suppression is mediated, among other factors, by regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs). Towards a better understanding and, eventually, manipulation of the immune-regulatory mechanisms in transplanted MM patients, we retrospectively sought a correlation between DLI outcome and circulating CD14(+) MDSCs, CD14(-) MDSCs and Tregs in 53 MM patients before their first DLI. We found significantly elevated frequencies of highly suppressive CD14(+) MDSCs, CD14(-) MDSCs and Tregs in pre-DLI samples from patients. Higher frequencies of Tregs, but not of MDSCs, were significantly associated with non-responsiveness to DLI. Furthermore, a lower frequency of Tregs predicted the development of chronic GVHD, which, in turn, displayed a high association with GVT. Elevated Treg frequencies before DLI were also associated with significantly shorter PFS and OS. Hence, our data reinforce the idea of active suppression of antitumor responses by Tregs in MM patients and therefore suggest that targeting patient Tregs before DLI may improve outcome of DLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.